{"filing":{"accession_number":"0001213900-26-086244","cik":"0001894525","ticker":"APUS","company_name":"Apimeds Pharmaceuticals US, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-05","primary_document":"ea0301025-8k_apimeds.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026086244/ea0301025-8k_apimeds.htm"},"events":[{"id":24701,"run_id":22397,"accession_number":"0001213900-26-086244","anchor_item_number":"8.01","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Dr. Christopher Kim as Chief Scientific Officer, effective immediately on August 5, 2026. As CSO, he will lead scientific, clinical, and regulatory development of the Company's primary APITOX program. This is a material executive appointment to a senior leadership role overseeing the company's core development strategy and regulatory pathway.","company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":25352,"accession_number":"0001213900-26-086244","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Christopher Kim as Chief Scientific Officer, effective immediately on August 5, 2026. As CSO, he will lead scientific, clinical, and regulatory development of the Company's primary APITOX program. This is a material executive appointment to a senior leadership role overseeing the company's core development strategy and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:40:04.652643+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25352,"accession_number":"0001213900-26-086244","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Christopher Kim as Chief Scientific Officer, effective immediately on August 5, 2026. As CSO, he will lead scientific, clinical, and regulatory development of the Company's primary APITOX program. This is a material executive appointment to a senior leadership role overseeing the company's core development strategy and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:40:04.652643+00:00","company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","filing_date":"2026-08-06"}]}